StreetAlpha.app
Home › Stocks › CTMX

CytomX Therapeutics, Inc. (CTMX)

Healthcare
$1.94
▼ −2.27%
LAST CLOSE · NOV 17

CytomX Therapeutics develops cancer treatments using its PROBODY masked biologics platform. It last closed at $1.94 on Nov 17, down 2.27% on the day. In the past 30 days there were 1 dark pool print totaling $254K, the largest $254K.

AI Auto Pilots
Is CTMX in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$14.0M
−87.7% vs a year ago
Net income
−$85.4M
−404.9% vs a year ago
Free cash flow
−$51.0M
−363.6% margin
Operating margin
−676.4%
−$94.9M operating income
Valuation
Market cap
$422.9M
218.0M shares
P/E
–
Price to sales
30.1
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$34.0M
At Sep 30
Shareholder equity
$284.9M
Shares outstanding
218.0M
At Oct 31
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $37.3M$37.3MFY2021FY2022: $53.2M$53.2MFY2022FY2023: $101.2M$101.2MFY2023FY2024: $138.1M$138.1MFY2024FY2025: $76.2M$76.2MFY2025

From CTMX's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Last report
Nov 5
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
1 Buy
1 firm · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Buy
1firm
1 Buy0 Hold0 Sell
Only 1 firm rated CTMX in the past 90 days, not enough for a consensus
Average 12-month target
$12.00
▲ 518.6% upside

Based on 1 analyst who set a price target on CTMX in the past 90 days. The average target is $12.00, with a high of $12.00 and a low of $12.00, compared with the last close of $1.94.

Low $12.00Avg $12.00High $12.00
Blue marker: last close $1.94
Highest target$12.00
Average target$12.00
Lowest target$12.00
Latest rating changes
WedbushMaintained
Nov 6Buy$12
JP MorganTarget lowered
Aug 13Buy$12 → $11
GuggenheimMaintained
Aug 10Buy$14
JP MorganUpgrade
Mar 16Buy$12
DateFirmActionRatingPrice target
Nov 6WedbushMaintainedBuy$12
Aug 13JP MorganTarget loweredBuy$12 → $11
Aug 10GuggenheimMaintainedBuy$14
Mar 16JP MorganUpgradeBuy$12
Loading…

Technical Analysis

CTMX · as of the Nov 17 close · updated after every close
Downtrend, nearing oversold

The stock is 13% below its 20 day and 29% below its 50 day average. It is 89% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 36), near oversold. The nearest support is the Pivot S1 at $1.91, and the nearest resistance the Pivot at $1.95.

Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityHigh, 8.5%/day
Key levels
$8.2152 week high+323.2%
$3.67200 day average+89.2%
$2.99100 day average+54.1%
$2.5050 day average+28.9%
$2.42Swing high (Oct 29)+24.7%
$2.1920 day average+12.9%
$1.98Pivot R1+2.1%
$1.95Pivot+0.5%
$1.94Last close
$1.91Pivot S1−1.5%
$1.9052 week low−2.1%
$1.90Swing low (Nov 10)−2.1%
Indicators
RSI (14)36.17Weak, oversold below 30Neutral
MACD-0.15Below its signal lineBearish
Stochastic17.0Near the bottom of its rangeOversold
ADX (14)25.2Trending down
Williams %R-92.3Oversold below −80, overbought above −20Oversold
CCI (20)-135.6Oversold below −100, overbought above 100Oversold
Rate of change−11.0%Change over 10 sessionsBearish
ATR (14)$0.16Typical daily range, 8.5% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for CTMX

What happened before

See how CTMX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow CTMX usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How CTMX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2015.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in CTMX in the last 90 days.

Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
1
Notional
$254K
Largest print
$254K
Loading…

CTMX Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲106 buying vs 65 selling
  • ▲Held by funds +1.2 pts
  • ▲Funds holding +15
  • ▲Superinvestors: 2 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding194179+8.4%
In funds' top 1002−100.0%
Held by funds99.1%97.9%+1.2 pts
New / increased39 / 6745 / 72−9.4%
Reduced / sold out42 / 2333 / 46−17.7%
Put/call ratio1.730.56+208.7%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See CTMX institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether CTMX is in one of them and how their past CTMX trades turned out.

CTMX in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered CTMX in an article yet. Here's the latest on the wider market.

About CytomX Therapeutics

CytomX Therapeutics is a biopharmaceutical company based in South San Francisco, California, that develops cancer treatments. It uses its PROBODY platform to build masked biologic therapies, which are designed to bind more selectively within tumors and limit effects on healthy tissue. Its most advanced candidate, Varsetatug Masetecan, is an antibody drug conjugate being studied in colorectal cancer, with plans to test it in other solid tumors. The company's therapies are aimed at cancer patients.

Headquarters
South San Francisco, CA